| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGEF18 |
| Uniprot No | Q6ZSZ5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1361aa |
| 氨基酸序列 | MGDDQEDDFPRRLSESMEDLSLDLGALQGSEYLQDLGLGAPSHSQPGETPDSRPTGEEPGRDSLFSSLAGSQDLSRRRSWERSRSCSESWRRLSLDASAVDEEPCLPRTLASLALNLPGGGLKTWTQGCLSGGGTPAESPGKECDSPKKRGRSRSVPVSFYEIRSPEISPGLEVPTPPVQGLEPPVLECMEKDHVEPDHVLIVQQVLQELRQYHGARQRACMSASPGGAHSNLTWFEFLSESEDGAGKNEKSDKSTSVKRRLSCLRSRVTRQKEKGKSPAHLKDKGQDARERRECVNGHQLLQGTFSGPSSCPLCGKPFLSSASLKEHPRGTLLSDGSPALSRNVGMTVSQKGGPQPTPSPAGPGTQLGPITGEMDEADSAFLKFKQTADDSLSLTSPNTESIFVEDPYTASLRSEIESDGHEFEAESWSLAVDAAYAKKQKREVVKRQDVLYELMQTEVHHVRTLKIMLKVYSRALQEELQFSSKAIGRLFPCADDLLETHSHFLARLKERRQESLEEGSDRNYVIQKIGDLLVQQFSGENGERMKEKYGVFCSGHNEAVSHYKLLLQQNKKFQNLIKKIGNFSIVRRLGVQECILLVTQRITKYPVLVERIIQNTEAGTEDYEDLTQALNLIKDIISQVDAKVSECEKGQRLREIAGKMDLKSSSKLKNGLTFRKEDMLQRQLHLEGMLCWKTTSGRLKDILAILLTDVLLLLQEKDQKYVFASVDSKPPVISLQKLIVREVANEEKAMFLISASLQGPEMYEIYTSSKEDRNAWMAHIQRAVESCPDEEEGPFSLPEEERKVVEARATRLRDFQERLSMKDQLIAQSLLEKQQIYLEMAEMGGLEDLPQPRGLFRGGDPSETLQGELILKSAMSEIEGIQSLICRQLGSANGQAEDGGSSTGPPRRAETFAGYDCTNSPTKNGSFKKKVSSTDPRPRDWRGPPNSPDLKLSDSDIPGSSEESPQVVEAPGTESDPRLPTVLESELVQRIQTLSQLLLNLQAVIAHQDSYVETQRAAIQEREKQFRLQSTRGNLLLEQERQRNFEKQREERAALEKLQSQLRHEQQRWERERQWQHQELERAGARLQEREGEARQLRERLEQERAELERQRQAYQHDLERLREAQRAVERERERLELLRRLKKQNTAPGALPPDTLAEAQPPSHPPSFNGEGLEGPRVSMLPSGVGPEYAERPEVARRDSAPTENRLAKSDVPIQLLSATNQFQRQAAVQQQIPTKLAASTKGGKDKGGKSRGSQRWESSASFDLKQQLLLNKLMGKDESTSRNRRSLSPILPGRHSPAPPPDPGFPAPSPPPADSPSEGFSLKAGGTALLPGPPAPSPLPATPLSAKEDASKEDVIFF |
| 预测分子量 | 151,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARHGEF18重组蛋白的假设参考文献示例(仅供参考，非真实文献)：
---
1. **文献名称**：*ARHGEF18 regulates endothelial cell polarity through RhoA activation*
**作者**：Smith J, et al.
**摘要**：本研究利用重组ARHGEF18蛋白，揭示了其通过激活RhoA GTP酶调控内皮细胞极性和屏障功能的分子机制。实验表明，重组ARHGEF18可直接结合并激活RhoA，影响细胞骨架重排。
2. **文献名称**：*Structural insights into ARHGEF18-mediated nucleotide exchange on RhoGTPases*
**作者**：Chen L, et al.
**摘要**：通过表达并纯化ARHGEF18重组蛋白，结合X射线晶体学解析其三维结构，发现其DH/PH结构域的关键氨基酸残基对Rho家族GTP酶的鸟苷酸交换活性至关重要。
3. **文献名称**：*ARHGEF18 promotes cancer cell invasion via recombinant protein-based signaling assays*
**作者**：Wang Y, et al.
**摘要**：利用重组ARHGEF18蛋白进行体外功能实验，证明其通过激活RhoC信号通路增强癌细胞迁移和侵袭能力，为靶向ARHGEF18的抗癌策略提供依据。
4. **文献名称**：*ARHGEF18 interacts with Par3 to regulate synaptic development*
**作者**：Kimura T, et al.
**摘要**：通过重组蛋白互作实验，发现ARHGEF18与极性蛋白Par3直接结合，调控神经元突触发育，提示其在神经系统中的潜在作用。
---
**注**：以上文献为模拟示例，实际研究需参考真实发表的论文。建议通过PubMed或Web of Science检索关键词“ARHGEF18 recombinant”或“ARHGEF18 RhoGEF”获取准确文献。
ARHGEF18 (Rho/Rac Guanine Nucleotide Exchange Factor 18), also known as p114RhoGEF, is a member of the RhoGEF family that regulates Rho GTPase signaling pathways by catalyzing the exchange of GDP for GTP on specific Rho proteins, predominantly RhoA. This protein plays a critical role in maintaining cell polarity, cytoskeletal reorganization, and cell-cell adhesion, particularly in epithelial and endothelial tissues. Structurally, ARHGEF18 contains a Dbl homology (DH) domain responsible for its GEF activity and a pleckstrin homology (PH) domain involved in membrane targeting and protein interactions.
Recombinant ARHGEF18 protein is engineered through molecular cloning techniques, typically expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its production enables detailed biochemical studies, including enzyme kinetics, interaction mapping, and structural analysis. Researchers utilize this recombinant protein to investigate its role in RhoA-mediated signaling cascades, such as regulating actomyosin contractility, tight junction assembly, and epithelial barrier integrity. Dysregulation of ARHGEF18 has been implicated in pathological conditions, including cancer metastasis, hypertension, and inflammatory diseases, making it a potential therapeutic target.
Studies using recombinant ARHGEF18 have also shed light on its involvement in developmental processes and cellular responses to mechanical stress. Its application extends to high-throughput drug screening to identify modulators of RhoA activity, offering avenues for novel treatments targeting cytoskeleton-related disorders. The availability of purified ARHGEF18 recombinant protein thus serves as a vital tool for dissecting Rho GTPase signaling mechanisms and their broader physiological impacts.
×
